<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Mar 18)
Becker M, Dulovic A, et int., and Schneiderhan-Marra N. [‚ÄúImmune response to SARS-CoV-2 variants of concern in vaccinated individuals.‚Äù](/search/?article=Becker21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.08.21252958](https://doi.org/10.1101/2021.03.08.21252958).
### Database Entries (Mar 18)
Brown JC, Goldhill DH, et int., and Barclay WS. [‚ÄúIncreased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape.‚Äù](/search/?article=Brown21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.24.432576](https://doi.org/10.1101/2021.02.24.432576).
### Database Entries (Mar 18)
Dejnirattisai W, Zhou D, et int., and Screaton GR. [‚ÄúAntibody evasion by the Brazilian P.1 strain of SARS-CoV-2.‚Äù](/search/?article=Dejnirattisai21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.12.435194](https://doi.org/10.1101/2021.03.12.435194).
### Database Entries (Mar 18)
Ku Z, Xie X, et int., and An Z. [‚ÄúMolecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.‚Äù](/search/?article=Ku21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-020-20789-7](https://doi.org/10.1038/s41467-020-20789-7). \[[PubMed33473140](https://www.ncbi.nlm.nih.gov/pubmed/33473140/)\] \[[PMC7817669](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817669/)\]
### Database Entries (Mar 18)
Madhi SA, Baillie V, et int., and Izu A. [‚ÄúSafety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa.‚Äù](/search/?article=Madhi21) _medRxiv_, 2021. [doi.org/10.1101/2021.02.10.21251247](https://doi.org/10.1101/2021.02.10.21251247).
### Database Entries (Mar 18)
Resende PC, Gr√§f T, et int., and Siqueira MM. [‚ÄúA potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil.‚Äù](/search/?article=Resende21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.12.434969](https://doi.org/10.1101/2021.03.12.434969).
### Database Entries (Mar 18)
Supasa P, Zhou D, et int., and Screaton GR. [‚ÄúReduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.‚Äù](/search/?article=Supasa21) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.02.033](https://doi.org/10.1016/j.cell.2021.02.033).
### Database Entries (Mar 18)
Zhou D, Dejnirattisai W, et int., and Screaton GR. [‚ÄúEvidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.‚Äù](/search/?article=Zhou21b) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.02.037](https://doi.org/10.1016/j.cell.2021.02.037). \[[PubMed33730597](https://www.ncbi.nlm.nih.gov/pubmed/33730597/)\]
### Database Entries (Mar 14)
Cathcart AL, Havenar-Daughton C, et int., and Hebner CM. [‚ÄúThe dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2.‚Äù](/search/?article=Cathcart21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.09.434607](https://doi.org/10.1101/2021.03.09.434607).
### Database Entries (Mar 14)
Copin R, Baum A, et int., and Kyratsous CA. [‚ÄúIn vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans.‚Äù](/search/?article=Copin21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.10.434834](https://doi.org/10.1101/2021.03.10.434834).
### Database Entries (Mar 14)
Deng X, Garcia-Knight MA, et int., and Chiu CY. [‚ÄúTransmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.‚Äù](/search/?article=Deng21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.07.21252647](https://doi.org/10.1101/2021.03.07.21252647).
### Database Entries (Mar 14)
Wang R, Zhang Q, et int., and Zhang L. [‚ÄúSpike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization.‚Äù](/search/?article=Wang21f) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.09.434497](https://doi.org/10.1101/2021.03.09.434497).
### Database Entries (Mar 14)
Widera M, Wilhelm A, et int., and Ciesek S. [‚ÄúBamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro.‚Äù](/search/?article=Widera21) _medRxiv_, 2021. [doi.org/10.1101/2021.02.24.21252372](https://doi.org/10.1101/2021.02.24.21252372).

### [Clinical Trials (Mar 11)](/page/updates/#clinical.trials)
[3 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-03-11)

### New Variants (Mar 09)

- [B.1.1.7 with S:E484K](https://covdb.stanford.edu/page/mutation-viewer/#sec_b-1-1-7-484k)

### Susceptibility data updated (Mar 09)

- [Susceptibility data](https://covdb.stanford.edu/page/susceptibility-data/)

### New Variants (Mar 09)

- [PHL-B.1.1.28](https://covdb.stanford.edu/page/mutation-viewer/#phl-b.1.1.28)

### Database Entries (Mar 09)
Faulkner N, Ng KW, et int., and Kassiotis G. [‚ÄúReduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.‚Äù](/search/?article=Faulkner21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.01.433314](https://doi.org/10.1101/2021.03.01.433314).
### Database Entries (Mar 09)
L√≥pez-Medina E, L√≥pez P, et int., and Caicedo I. [‚ÄúEffect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19.‚Äù](/search/?article=Lopez-Medina21) _JAMA_, 2021. [doi.org/10.1001/jama.2021.3071](https://doi.org/10.1001/jama.2021.3071). \[[PubMed33662102](https://www.ncbi.nlm.nih.gov/pubmed/33662102/)\]
### Database Entries (Mar 09)
Marot S, Malet I, et int., and Marcelin A. [‚ÄúNeutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers.‚Äù](/search/?article=Marot21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.05.434089](https://doi.org/10.1101/2021.03.05.434089).
### Database Entries (Mar 09)
Moyo-Gwete T, Madzivhandila M, et int., and Moore PL. [‚ÄúSARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.‚Äù](/search/?article=Moyo-Gwete21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.06.434193](https://doi.org/10.1101/2021.03.06.434193).
### Database Entries (Mar 09)
Rondinone V, Pace L, et int., and Galante D. [‚ÄúVOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy.‚Äù](/search/?article=Rondinone21) _Viruses_, 2021. [doi.org/10.3390/v13020276](https://doi.org/10.3390/v13020276). \[[PubMed33670182](https://www.ncbi.nlm.nih.gov/pubmed/33670182/)\] \[[PMC7916909](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916909/)\]
### Database Entries (Mar 09)
Tablizo FA, Kim KM, et int., and Saloma CP. [‚ÄúGenome sequencing and analysis of an emergent SARS-CoV-2 variant characterized by multiple spike protein mutations detected from the Central Visayas Region of the Philippines.‚Äù](/search/?article=Tablizo21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.03.21252812](https://doi.org/10.1101/2021.03.03.21252812).
### Database Entries (Mar 09)
Trinit√© B, Pradenas E, et int., and Blanco J. [‚ÄúPrevious SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.‚Äù](/search/?article=Trinite21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.05.433800](https://doi.org/10.1101/2021.03.05.433800).
### Database Entries (Mar 09)
Wang P, Wang M, et int., and Ho DD. [‚ÄúIncreased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization.‚Äù](/search/?article=Wang21d) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.01.433466](https://doi.org/10.1101/2021.03.01.433466).
### Database Entries (Mar 09)
Wang L, Zhou T, et int., and Misasi J. [‚ÄúAntibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.‚Äù](/search/?article=Wang21e) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.25.432969](https://doi.org/10.1101/2021.02.25.432969). \[[PubMed33655252](https://www.ncbi.nlm.nih.gov/pubmed/33655252/)\] \[[PMC7924272](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924272/)\]
### [Clinical Trials (Mar 04)](/page/updates/#clinical.trials)
[3 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-03-04)
### Database Entries (Mar 03)
Bessi√®re P, Wasniewski M, et int., and Volmer R. [‚ÄúIntranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model.‚Äù](/search/?article=Bessiere21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.09.430458](https://doi.org/10.1101/2021.02.09.430458).
### Database Entries (Mar 03)
Good SS, Westover J, et int., and Sommadossi J. [‚ÄúAT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19.‚Äù](/search/?article=Good21) _Antimicrobial Agents and Chemotherapy_, 2021. [doi.org/10.1128/aac.02479-20](https://doi.org/10.1128/aac.02479-20). \[[PubMed33558299](https://www.ncbi.nlm.nih.gov/pubmed/33558299/)\]
### Database Entries (Mar 03)
Li Q, Nie J, et int., and Wang Y. [‚ÄúNo higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants.‚Äù](/search/?article=Li21c) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.02.042](https://doi.org/10.1016/j.cell.2021.02.042).
### Database Entries (Mar 03)
Rosenke K, Hansen F, et int., and Jarvis M. [‚ÄúOrally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.‚Äù](/search/?article=Rosenke20c) _Research square_, 2020. [doi.org/10.21203/rs.3.rs-86289/v1](https://doi.org/10.21203/rs.3.rs-86289/v1). \[[PubMed33052329](https://www.ncbi.nlm.nih.gov/pubmed/33052329/)\] \[[PMC7553153](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553153/)\]
### Database Entries (Mar 03)
Wahl A, Gralinski LE, et int., and Garcia JV. [‚ÄúSARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.‚Äù](/search/?article=Wahl21) _Nature_, 2021. [doi.org/10.1038/s41586-021-03312-w](https://doi.org/10.1038/s41586-021-03312-w). \[[PubMed33561864](https://www.ncbi.nlm.nih.gov/pubmed/33561864/)\]
### [Clinical Trials (Feb 25)](/page/updates/#clinical.trials)
[3 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-02-25)
### Database Entries (Feb 23)
Diamond M, Chen R, et int., and Gilchuk P. [‚ÄúSARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.‚Äù](/search/?article=Diamond21) _Research square_, 2021. [doi.org/10.21203/rs.3.rs-228079/v1](https://doi.org/10.21203/rs.3.rs-228079/v1). \[[PubMed33594356](https://www.ncbi.nlm.nih.gov/pubmed/33594356/)\] \[[PMC7885928](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885928/)\]
### Database Entries (Feb 23)
Garcia-Beltran WF, Lam EC, et int., and Balazs AB. [‚ÄúCirculating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.‚Äù](/search/?article=Garcia-Beltran21) _medRxiv_, 2021. [doi.org/10.1101/2021.02.14.21251704](https://doi.org/10.1101/2021.02.14.21251704). \[[PubMed33619506](https://www.ncbi.nlm.nih.gov/pubmed/33619506/)\] \[[PMC7899476](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899476/)\]
### Database Entries (Feb 23)
Hoffmann M, Zhang L, et int., and P√∂hlmann S. [‚ÄúSARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.‚Äù](/search/?article=Hoffmann21b) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.12.430998](https://doi.org/10.1101/2021.02.12.430998).
### Database Entries (Feb 23)
Liu Y, Liu J, et int., and Shi P. [‚ÄúNeutralizing Activity of BNT162b2-Elicited Serum ‚Äî Preliminary Report.‚Äù](/search/?article=Liu21b) _New England Journal of Medicine_, 2021. [doi.org/10.1056/NEJMc2102017](https://doi.org/10.1056/NEJMc2102017). \[[PubMed33596352](https://www.ncbi.nlm.nih.gov/pubmed/33596352/)\]
### Database Entries (Feb 23)
Planas D, Bruel T, et int., and Schwartz O. [‚ÄúSensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.‚Äù](/search/?article=Planas21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.12.430472](https://doi.org/10.1101/2021.02.12.430472).
### Database Entries (Feb 23)
Tada T, Dcosta BM, et int., and Landau NR. [‚ÄúDecreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.‚Äù](/search/?article=Tada21b) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.18.431897](https://doi.org/10.1101/2021.02.18.431897). \[[PubMed33619484](https://www.ncbi.nlm.nih.gov/pubmed/33619484/)\] \[[PMC7899448](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899448/)\]
### Database Entries (Feb 23)
West AP, Barnes CO, et int., and Bjorkman PJ. [‚ÄúSARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape.‚Äù](/search/?article=West21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.14.431043](https://doi.org/10.1101/2021.02.14.431043).
### Database Entries (Feb 23)
Yuan M, Huang D, et int., and Wilson IA. [‚ÄúStructural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.‚Äù](/search/?article=Yuan21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.16.430500](https://doi.org/10.1101/2021.02.16.430500). \[[PubMed33619487](https://www.ncbi.nlm.nih.gov/pubmed/33619487/)\] \[[PMC7899451](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899451/)\]
### Database Entries (Feb 16)
Dampalla CS, Zhang J, et int., and Chang K. [‚ÄúPost-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.‚Äù](/search/?article=Dampalla21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.05.429937](https://doi.org/10.1101/2021.02.05.429937).
### Database Entries (Feb 16)
Lu Q, Zhang Z, et int., and Tong A. [‚ÄúDevelopment of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.‚Äù](/search/?article=Lu21) _Journal of Nanobiotechnology_, 2021. [doi.org/10.1186/s12951-021-00768-w](https://doi.org/10.1186/s12951-021-00768-w). \[[PubMed33514385](https://www.ncbi.nlm.nih.gov/pubmed/33514385/)\] \[[PMC7844813](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844813/)\]
### Database Entries (Feb 16)
Martinez DR, Schaefer A, et int., and Sheahan TP. [‚ÄúEarly therapy with remdesivir and antibody combinations improves COVID-19 disease in mice.‚Äù](/search/?article=Martinez21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.27.428478](https://doi.org/10.1101/2021.01.27.428478). \[[PubMed33532765](https://www.ncbi.nlm.nih.gov/pubmed/33532765/)\] \[[PMC7852229](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852229/)\]
### Database Entries (Feb 16)
Miao X, Luo Y, et int., and Xu Y. [‚ÄúA novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.‚Äù](/search/?article=Miao20) _mAbs_, 2020. [doi.org/10.1080/19420862.2020.1804241](https://doi.org/10.1080/19420862.2020.1804241). \[[PubMed32804015](https://www.ncbi.nlm.nih.gov/pubmed/32804015/)\] \[[PMC7531490](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531490/)\]
### Database Entries (Feb 16)
Reuschl A, Thorne LG, et int., and Krogan NJ. [‚ÄúHost-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.‚Äù](/search/?article=Reuschl21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.24.427991](https://doi.org/10.1101/2021.01.24.427991). \[[PubMed33501437](https://www.ncbi.nlm.nih.gov/pubmed/33501437/)\] \[[PMC7836107](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836107/)\]
### Database Entries (Feb 16)
Valenzuela Nieto G, Jara R, et int., and Rojas-Fernandez A. [‚ÄúPotent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.‚Äù](/search/?article=ValenzuelaNieto21) _Scientific Reports_, 2021. [doi.org/10.1038/s41598-021-82833-w](https://doi.org/10.1038/s41598-021-82833-w). \[[PubMed33558635](https://www.ncbi.nlm.nih.gov/pubmed/33558635/)\] \[[PMC7870875](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870875/)\]
### Database Entries (Feb 16)
Zhou Y, Liu Z, et int., and Wang Q. [‚ÄúEnhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.‚Äù](/search/?article=Zhou21) _Cell Reports_, 2021. [doi.org/10.1016/j.celrep.2021.108699](https://doi.org/10.1016/j.celrep.2021.108699). \[[PubMed33485405](https://www.ncbi.nlm.nih.gov/pubmed/33485405/)\] \[[PMC7802522](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802522/)\]
### [Clinical Trials (Feb 11)](/page/updates/#clinical.trials)
[6 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-02-11)
### Database Entries (Feb 10)
Huang Y, Nguyen AW, et int., and Maynard JA. [‚ÄúIdentification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses.‚Äù](/search/?article=Huang21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.31.428824](https://doi.org/10.1101/2021.01.31.428824).
### Database Entries (Feb 10)
Koenig P, Das H, et int., and Schmidt FI. [‚ÄúStructure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.‚Äù](/search/?article=Koenig21) _Science_, 2021. [doi.org/10.1126/science.abe6230](https://doi.org/10.1126/science.abe6230). \[[PubMed33436526](https://www.ncbi.nlm.nih.gov/pubmed/33436526/)\]
### Database Entries (Feb 10)
Wang C, van Haperen R, et int., and Bosch B. [‚ÄúIsolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein.‚Äù](/search/?article=Wang21c) _bioRxiv_, 2020. [doi.org/10.1101/2020.10.20.346916](https://doi.org/10.1101/2020.10.20.346916).
### Database Entries (Feb 09)
Joaqu√≠n C√°ceres C, Cardenas-Garcia S, et int., and Perez DR. [‚ÄúEfficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.‚Äù](/search/?article=Caceres21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.27.428428](https://doi.org/10.1101/2021.01.27.428428). \[[PubMed33532776](https://www.ncbi.nlm.nih.gov/pubmed/33532776/)\] \[[PMC7852269](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852269/)\]
### Database Entries (Feb 09)
Li W, Sch√§fer A, et int., and Dimitrov DS. [‚ÄúHigh Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models.‚Äù](/search/?article=Li20j) _Cell_, 2020. [doi.org/10.1016/j.cell.2020.09.007](https://doi.org/10.1016/j.cell.2020.09.007). \[[PubMed32941803](https://www.ncbi.nlm.nih.gov/pubmed/32941803/)\] \[[PMC7473018](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473018/)\]
### Database Entries (Feb 09)
Rappazzo CG, Tse LV, et int., and Walker LM. [‚ÄúBroad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.‚Äù](/search/?article=Rappazzo21) _Science_, 2021. [doi.org/10.1126/science.abf4830](https://doi.org/10.1126/science.abf4830). \[[PubMed33495307](https://www.ncbi.nlm.nih.gov/pubmed/33495307/)\]
